

**DRAFT - May 31, 2023**

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 21-23, 2023

**Wednesday, June 21, 2023**

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>8:30</b>	<b>Respiratory Syncytial Virus Vaccines - Adult</b>	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine	TBD (Pfizer)
	Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine	TBD (GSK)
	Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model)	Dr. David Hutton (University of Michigan)
	Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK)	Dr. Ismael Ortega Sanchez (CDC/NCIRD)
	Updated Evidence to Recommendations (incl. GRADE) and clinical considerations for 2 vaccines (Pfizer & GSK)	Dr. Michael Melgar (CDC/NCIRD)
<b>11:30</b>	<b><i>Break</i></b>	
<b>11:45</b>	<b>Polio Vaccine</b>	
	Introduction	Dr. Oliver Brooks (ACIP, WG Chair)
	Recommendations for Adult Polio Vaccination	Dr. Sarah Kidd (CDC/NCIRD)
<b>1:15</b>	<b><i>Break</i></b>	
<b>2:00</b>	<b>Influenza Vaccine</b>	
	Introduction	Dr. H. Keipp Talbot (ACIP, WG Chair)
	WG considerations and proposed recommendations	Dr. Lisa Grohskopf (CDC/NCIRD)
<b>4:00</b>	<b><i>Break</i></b>	
<b>4:15</b>	<b>Public Comment</b>	
<b>4:35</b>	<b><u>VOTES</u></b>	
	RSV Adult	
	Polio	
	Influenza	
<b>5:30</b>	<b>Adjourn</b>	

## DRAFT - May 19, 2023

**Thursday, June 22, 2023**

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>8:35</b>	<b>Agency Updates</b> <i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH</i>	
<b>8:55</b>	<b>Pneumo Vaccines</b>	
	Introduction	Dr. Kathy Poehling (ACIP, WG Chair)
	Economic analysis and public health impact of PCV20 use in children	Dr. Charles Stoecker (Tulane University)
	Comparison of cost-effectiveness analyses on PCV20 use in children	Dr. Ayabina Diepreye (CDC/NCIRD)
	Summary of WG interpretation on EtR and policy	Dr. Miwako Kobayashi (CDC/NCIRD)
<b>10:25</b>	<b>Break</b>	
<b>10:40</b>	<b>Dengue Vaccines</b>	
	Introduction	Dr. Wilbur Chen (ACIP, WG Chair)
	Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico	Guido Espana
	Cost effectiveness analysis for TAK-003 – CDC model and comparison to manufacturer model	Kaul Rajreni (CDC/NCIRD)
	Partial EtR (including GRADE) for TAK-003 – problem, benefits and harms, resource use	Dr. Laura E Adams (CDC/NCEZID)
<b>11:40</b>	<b>Break</b>	
<b>12:25</b>	<b>Chikungunya Vaccine</b>	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Chikungunya vaccine among U.S. travelers and healthcare providers	Ms. Nicole Lindsey (CDC/NCEZID)
	Chikungunya virus infection among laboratory workers	Dr. Susan Hills (CDC/NCEZID)
	Update on large chikungunya outbreak in Paraguay	Dr. Susan Hills (CDC/NCEZID)
	Workgroup considerations	Dr. Susan Hills (CDC/NCEZID)
<b>1:25</b>	<b>Break</b>	
<b>1:40</b>	<b>Respiratory Syncytial Virus Vaccines - Pediatric/Maternal</b>	
	Introduction	Dr. Sarah Long (ACIP, WG Chair)
	CDC model cost-effectiveness of Pfizer maternal RSVpreF vaccine	Dr. David Hutton (University of Michigan)
	Comparison of manufacturer and CDC cost-effectiveness models of Pfizer maternal RSVpreF vaccine	Dr. Ismael Ortega Sanchez (CDC/NCIRD)
	Pfizer maternal RSVpreF vaccine evidence to recommendations (EtR), and clinical considerations	Dr. Katherine Fleming-Dutra (CDC/NCIRD)
	Comparison of cost-effectiveness analyses for nirsevimab and Pfizer maternal RSVpreF vaccine	Dr. David Hutton (University of Michigan)
	Combined clinical considerations for use of nirsevimab and Pfizer maternal RSVpreF vaccine	Dr. Jefferson Jones (CDC, NCIRD)
<b>4:40</b>	<b>Break</b>	
<b>4:50</b>	<b>Public Comment</b>	
<b>5:10</b>	<b>VOTES</b>	
	<b>Pneumococcal</b>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>5:30</b>	<b>Adjorn</b>	

## DRAFT - May 19, 2023

### Friday, June 23, 2023

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair)
<b>8:10</b>	<b>Mpox Vaccine</b>	
	Introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
	Epidemiology update	Dr. Faisal Minhaj (CDC/NCEZID)
	Vaccine effectiveness update	Dr. Ian Kracalik (CDC/NCEZID)
	Clinical considerations for use of JYNNEOS during mpox outbreaks	Dr. Agam Rao (CDC/NCEZID)
<b>10:10</b>	<b>Break</b>	
<b>10:20</b>	<b>Meningococcal Vaccines</b>	
	Introduction	Dr. Kathy Poehling (ACIP, WG Chair)
	Cost effectiveness analysis	Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
	GRADE/EtR	Dr. Sam Crowe (CDC/NCIRD)
	Summary and workgroup considerations	Dr. Sam Crowe (CDC/NCIRD)
<b>11:35</b>	<b>Break</b>	
<b>11:45</b>	<b>Vaccine Safety</b>	TBD
<b>12:30</b>	<b>Break</b>	
<b>12:40</b>	<b>COVID-19 Vaccines</b>	
	Introduction	Dr. Matthew Daley (ACIP WG Chair)
	COVID-19 epidemiologic data for populations of focus	TBD
	Infection-induced and hybrid immunity	Dr. Jefferson Jones (CDC/NCIRD)
	COVID-19 vaccine effectiveness updates	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Summary and work group considerations	TBD
<b>2:40</b>	<b>Adjorn</b>	

### **Acronyms**

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness